Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06926348

Assessment of Usability and Preliminary Effectiveness of a Digital Sleep Aid in an Italian Sample

Chronic insomnia affects approximately 30% of the Italian population, leading to significant impairments in daily functioning and overall health. While Cognitive Behavioral Therapy for Insomnia (CBT-I) is the recommended first-line treatment, access is limited due to a shortage of trained specialists and resources within the Italian healthcare system. This study aims to evaluate the usability, acceptability, and preliminary effectiveness of a mobile application designed to assist individuals with chronic insomnia. The app offers digital sleep diaries, personalized sleep hygiene education, relaxation exercises, and an interactive chatbot to promote healthy sleep behaviors. Fifty adult participants diagnosed with chronic insomnia will be randomly assigned to either the intervention group, which will use the mobile application alongside their usual treatment, or to a control group receiving only standard care. The primary outcomes will assess the app's usability and participants' adherence to sleep hygiene practices. Secondary outcomes will evaluate changes in insomnia severity, mood, and quality of life. Assessments will occur at the start of the study, after the 8-week intervention, and at a 6-month follow-up to explore the intervention's long-term effects.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ospedale Borgo Roma - Neurologia B

Verona, 37129, Italy

Location status: Recruiting

Location contact

Elena Antelmi, Professor - Neurology

CONTACT

[email protected]

3293526335

Elena Antelmi, Professor - Neurology

PRINCIPAL_INVESTIGATOR

Giacomo Carollo, MSc - Psychology

CONTACT

[email protected]

+393454361133

Giacomo Carollo, MSc - Psychology

SUB_INVESTIGATOR

About this study

This randomized controlled pilot trial evaluates a Digital Health Technology (DHT) developed as a Health & Wellness tool aimed at supporting individuals diagnosed with chronic insomnia. Chronic insomnia significantly impacts quality of life and poses a considerable burden on healthcare systems. Despite Cognitive Behavioral Therapy for Insomnia (CBT-I) being the recommended first-line treatment, its limited accessibility in Italy necessitates scalable and innovative solutions. The DHT under investigation is a mobile application developed collaboratively by the University of Verona and private-sector partners, designed specifically for educational purposes and the promotion of healthy sleep behaviors.

The intervention is structured over an 8-week period, during which participants are expected to engage daily with the application. The DHT includes several core functionalities:

Digital Sleep Diaries: Participants document their sleep habits daily, including sleep onset latency, total sleep duration, wake after sleep onset, and sleep efficiency. This self-monitoring aims to increase sleep-awareness and encourage consistent engagement with healthy sleep behaviors.

Personalized Educational Content: Users gain access to educational modules designed according to CBT-I principles. Topics include optimizing the sleep environment, maintaining consistent sleep schedules, managing lifestyle factors affecting sleep, and addressing common misconceptions about sleep.

Relaxation and Mindfulness Exercises: The app provides guided audio and video exercises focusing on relaxation techniques such as deep breathing and progressive muscle relaxation, alongside mindfulness practices intended to reduce pre-sleep arousal and facilitate better sleep.

Interactive Chatbot: An integrated conversational agent assists users in navigating app functionalities, provides personalized reminders, motivational feedback, and real-time assistance, enhancing user engagement and compliance.

Participants (N=50) are recruited from the outpatient clinic at Borgo Roma Hospital, Verona. Eligible individuals are randomly assigned in a 1:1 ratio to either receive the DHT intervention combined with Treatment as Usual (DHT + TAU), or Treatment as Usual (TAU) alone. TAU involves standardized educational materials on sleep hygiene practices provided via printed booklets and continued management under the patient's usual healthcare provider.

Assessments are conducted at baseline (T0), immediately post-intervention (T1), and at a 6-month follow-up (T2). Primary outcomes focus on usability and acceptability, measured by the User Experience Questionnaire (UEQ), digital engagement metrics, and adherence to sleep hygiene practices via the Sleep Hygiene Index (SHI). Secondary outcomes assess preliminary efficacy regarding insomnia severity (Insomnia Severity Index - ISI), mood disturbances (Hospital Anxiety and Depression Scale - HADS), and overall health-related quality of life (Short Form Health Survey - SF-12).

Data collection employs the secure LimeSurvey platform to ensure participant confidentiality and data protection according to GDPR standards. Data analysis includes Linear Mixed Effects Models, exploratory analyses for identifying predictors of treatment response, and sensitivity analyses for assessing robustness of findings.

This feasibility trial aims to inform future large-scale studies by evaluating the potential benefits and limitations of using a scalable, non-medical DHT in the routine management of chronic insomnia. Results are anticipated to contribute substantially to the evidence base supporting digital interventions as viable adjuncts to standard care for insomnia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18 to 70 years
  • Diagnosis of chronic insomnia according to DSM-5 criteria
  • Willingness to participate in the study and provide informed consent
  • Personal active email address
  • Ownership of a compatible mobile device with internet access (for the DHT group)

Exclusion criteria

  • Medical conditions requiring hospital admission during the study period
  • Comorbid diagnosis of sleep-related breathing disorders
  • Neurological disorders affecting sleep (e.g., narcolepsy, parasomnias, epilepsy, neurodegenerative diseases)
  • Currently receiving psychological treatment for insomnia or planning to do so within the next 6 months
  • Incompatible smartphone or lack of internet access (for DHT group)

Treatment and study plan

Digital Health Technology for Chronic Insomnia

Behavioral

A mobile application designed to support chronic insomnia management through digital self-monitoring of sleep patterns, personalized sleep hygiene education, cognitive strategies, relaxation and mindfulness exercises, and chatbot interactions. Users receive tailored notifications and educational content to encourage healthy sleep behaviors over an 8-week period. Existing pharmacological treatments prescribed prior to study enrollment continue unchanged

Treatment as Usual (TAU)

Behavioral

Participants receive standard sleep hygiene recommendations via a printed educational booklet. They maintain printed sleep diaries for daily self-monitoring throughout the 8-week intervention. Existing pharmacological treatments prescribed prior to study enrollment continue unchanged.

Primary outcomes

  1. Usability and Acceptability of Digital Health Technology (DHT)

    Time frame: After 8 weeks of intervention (T1)

    Usability and acceptability measured by the User Experience Questionnaire (UEQ) and digital engagement metrics, including app access frequency, session duration, notification interactions, and drop-out rates.

  2. Adherence to Sleep Hygiene Practices

    Time frame: Baseline (T0), after 8 weeks (T1), and at 6-month follow-up (T2)

    Change in adherence to recommended sleep hygiene behaviors assessed through the Sleep Hygiene Index (SHI).

Secondary outcomes

  1. Insomnia Severity Index (ISI)

    Time frame: Baseline (T0), after 8 weeks (T1), and at 6-month follow-up (T2)

    Change in insomnia severity measured using the Insomnia Severity Index, evaluating subjective sleep disturbance and related daytime impairment.

  2. Mood and Emotional Distress

    Time frame: Baseline (T0), after 8 weeks (T1), and at 6-month follow-up (T2)

    Change in anxiety and depression symptoms assessed using the Hospital Anxiety and Depression Scale (HADS).

  3. Health-Related Quality of Life

    Time frame: Baseline (T0), after 8 weeks (T1), and at 6-month follow-up (T2)

    Change in quality of life across multiple dimensions (e.g., physical functioning, emotional wellbeing) assessed using the Short Form Health Survey (SF-12).

Study contacts

Contact information is provided by the study sponsor or research team.

Elena Antelmi, Professor - Neurology

CONTACT

[email protected]

+393293526335

Giacomo Carollo, MSc - Psychology

CONTACT

[email protected]

+393454361133

Sponsors and collaborators

Lead sponsor

Universita di Verona

Other

Collaborators

  • Fondazione RIDE2Med, Milan, Italy
  • QStep s.r.l. Verona, Italy
  • Santer Reply S.p.A. Milan, Italy
  • daVi Digital Medicine s.r.l. Verona, Italy

Registry information

Official study title

Usability, Acceptability, and Preliminary Effectiveness of a Digital Health Technology for Patient Monitoring of Chronic Insomnia Symptoms and the Promotion of Functional Sleep Behaviors: A Randomized Clinical Trial

Acronym: REST

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Apr 13, 2025
Registry last updated
Apr 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.